Stocks Health care MBX
NASDAQ · Health careMBX Biosciences, Inc. (MBX)
It posted a net loss of $145.1M. In fiscal 2025 capital spending exceeded operating cash flow by $81.9M. At September 30, 2026 it held $161.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about MBX Biosciences, Inc.
- Net worth
- MBX Biosciences, Inc. has a market value (market cap) of $2.6B at the latest share price, and shareholders' equity of $472.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $79.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- MBX Biosciences, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What MBX Biosciences, Inc. does
MBX Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MBX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$87M | -$2.38 | -$81.9M |
| 2024 | n/a | -$61.9M | -$5.82 | -$55.6M |
| 2024 | n/a | -$32.6M | -$31.96 | -$32.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What MBX Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- October 22, 2026
- August 27, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026Activist stake changed SCHEDULE 13D/A
- August 10, 2026Activist stake changed SCHEDULE 13D/A
- August 6, 2026
- August 6, 2026
Insider trades
What the people running MBX Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $20.1K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Azoulay SalomonChief Medical Officer | Sold | 373 | $20.1K |
| August 4, 2026 | Azoulay SalomonChief Medical Officer | Sold | 370 | $24.3K |
| August 3, 2026 | Hoerter Steven L.President and CEO, Director | Received as pay | 71,000 | - |
| August 3, 2026 | Smither John WChief Financial Officer | Received as pay | 28,000 | - |
| May 8, 2026 | Azoulay SalomonChief Medical Officer | Exercised options | 55,000 | $575.3K |
| May 8, 2026 | Azoulay SalomonChief Medical Officer | Soldpre-planned (10b5-1) | 55,000 | $2.1M |
| May 8, 2026 | Azoulay SalomonChief Medical Officer | Exercised options | 15,003 | $240K |
| May 8, 2026 | Azoulay SalomonChief Medical Officer | Soldpre-planned (10b5-1) | 15,003 | $574.6K |
Who owns MBX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| James N. Topper13D, may seek influence with 16 related filers | 18.8% | September 23, 2024 |
| Patrick J. Heron13D, may seek influence with 10 related filers | 11.7% | August 10, 2026 |
| New Enterprise Associates 17, L.P.13D, may seek influence with 11 related filers | 11.4% | September 23, 2024 |
| Fmr LLC13G, passive with 1 related filers | 11.2% | July 8, 2026 |
| Wellington Management Group LLP13G, passive with 3 related filers | 10.5% | July 8, 2026 |
| Edward T. Mathers13D, may seek influence with 11 related filers | 8.1% | November 10, 2025 |
| Norwest Venture Partners XVI, LP13D, may seek influence with 5 related filers | 6.4% | September 23, 2024 |
| Orbimed Advisors LLC13D, may seek influence with 2 related filers | 6.4% | August 10, 2026 |
| Paradigm BioCapital Advisors LP13G, passive with 3 related filers | 5.2% | June 24, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 173 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 6,652,013 | 0 |
| Fmr LLC | 5,322,885 | +2,386,201 |
| Wellington Management Group Llp | 4,977,523 | +1,785,699 |
| NEA Management Company, LLC | 3,614,486 | 0 |
| Orbimed Advisors LLC | 3,428,736 | -209,151 |
| BlackRock, Inc. | 3,323,672 | +382,266 |
| Paradigm Biocapital Advisors LP | 2,508,015 | new |
| Nvp Associates, LLC | 2,136,335 | 0 |
| Deep Track Capital, LP | 1,732,569 | -1,025,000 |
| Polar Capital Holdings Plc | 1,608,514 | -13,672 |
| Vanguard Capital Management LLC | 1,477,388 | -204 |
| Aaron Wealth Advisors LLC | 1,167,799 | -377 |
| Driehaus Capital Management LLC | 1,056,579 | +38,367 |
| Kynam Capital Management, LP | 934,799 | 0 |
| Woodline Partners LP | 900,092 | +29 |
| Eventide Asset Management, LLC | 873,492 | -16,508 |
| State Street Corp | 864,466 | +77,258 |
| Parkman Healthcare Partners LLC | 800,173 | +136 |
| Geode Capital Management, LLC | 773,072 | +102,687 |
| Braidwell LP | 710,880 | -781,587 |
Insiders
5 insiders reported holding 1,354,408 shares in total, about $73.2M at the last price.
| Holder | Shares |
|---|---|
| Hawryluk P. KentPresident & CEO, Director | 1,214,444486,777 held indirectly |
| Hoerter Steven L.President and CEO, Director | 82,938 |
| Smither John WChief Financial Officer | 28,000 |
| Bartram RichardChief Financial Officer | 15,000 |
| Azoulay SalomonChief Medical Officer | 14,026 |
Questions about MBX
What does MBX Biosciences, Inc. do?
MBX Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as MBX. Its shares trade on NASDAQ under the ticker MBX.
What is MBX Biosciences, Inc.'s net worth?
MBX Biosciences, Inc. has a market value (market cap) of $2.6B at the latest share price, and shareholders' equity of $472.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is MBX Biosciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $145.1M.
When did MBX Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is MBX Biosciences, Inc.'s next earnings report?
MBX Biosciences, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MBX with
Follow MBX
Get an email when MBX Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values MBX Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.